Live Breaking News & Updates on Sallyc Lau

Stay updated with breaking news from Sallyc lau. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Shared decision-making required when choosing first-line regimen for PD-L1-high NSCLC

CHICAGO — Chemoimmunotherapy and immunotherapy alone conferred comparable benefit as first-line therapy for most patients with advanced non-small cell lung cancer and high PD-L1 expression, results presented at ASCO Annual Meeting showed.Older patients appeared to derive better OS and PFS outcomes with immunotherapy alone, findings from the exploratory pooled analysis showed. ....

United States , Sallyc Lau , Oladimeji Akinboro , Hossein Borghaei , Mark Leiser ,